Roland Ugarte, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (60.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Procept Biorobotics Corporation at 32.8% of the total. Reporting peaked in 2023 at $1,924 and has fallen 70.8% since, to $563 in 2025.
Across 161 payments — averaging $57.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- Dendreon Pharmaceuticals LLC$2K
- Boston Scientific$999
- Axonics, Inc.$407
- Antares Pharma, Inc.$326
- Teleflex LLC$324
- plus $3K from 32 others
What the payments were for
- Consulting fees$1,32514%
- Travel & lodging$2,08322%
- Food & beverage$5,59460%
- Education$3223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 25 | $3,055 |
| Dendreon Pharmaceuticals LLC | 11 | $1,538 |
| Boston Scientific | 11 | $999 |
| Axonics, Inc. | 5 | $407 |
| Antares Pharma, Inc. | 24 | $326 |
| Teleflex LLC | 3 | $324 |
| SRS Medical Systems, Inc. | 2 | $293 |
| Coloplast | 16 | $279 |
| Histosonics, Inc. | 2 | $275 |
| Olympus America Inc. | 2 | $263 |
| Tolmar Pharmaceuticals, Inc. | 12 | $161 |
| Laborie Medical Technologies Corp. | 1 | $160 |
| Medtronic | 1 | $144 |
| Dornier Medtech America, Inc | 3 | $143 |
| Conmed Corporation | 1 | $138 |
| Agiliti Surgical, Inc. | 1 | $130 |
| Progenics Pharmaceuticals, Inc. | 5 | $89 |
| Johnson & Johnson | 5 | $84 |
| Merck | 3 | $50 |
| Telix Pharmaceuticals | 1 | $48 |
| Astellas Pharma US Inc | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 1 | $35 |
| Myovant Sciences Inc. | 2 | $33 |
| ABC Home Medical Supply, Inc. | 2 | $31 |
| Neotract Inc. | 2 | $31 |
| Convatec Inc. | 2 | $30 |
| Travere Therapeutics, Inc. | 4 | $25 |
| Photocure Inc | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Urogen Pharma, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Cure Medical LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$1,325
- AquaBeam Robotic System$1,256
- AQUABEAM SYSTEM$914
- AMS$396
- UroCuff$293
- Axonics$290
- iTIND System$263
- UroLift$149
- INTERSTIM$144
- AIRSEAL$138
- UroLift System$136
- Sonablate$130
- Lithotripters & Accessories$106
- SPACEOAR VUE$106
- ELIGARD$102
- ADVANCE$102
How this compares
$9,324 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 22 | $295,087 |
| GemtesaVibegron | 34 | $30,480 |
| MyrbetriqMirabegron | 54 | $29,267 |
| OrgovyxRelugolix | 11 | $26,091 |
| Tolterodine Tartrate ErTolterodine Tartrate | 182 | $15,793 |
| Tamsulosin Hcl | 836 | $14,650 |
| Finasteride | 491 | $8,251 |
| Tolterodine Tartrate | 100 | $5,992 |
| Oxybutynin Chloride ErOxybutynin Chloride | 153 | $3,460 |
| Cephalexin | 280 | $2,371 |
| Solifenacin Succinate | 37 | $1,981 |
| Doxazosin Mesylate | 97 | $1,759 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,410 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $944 |
| Megestrol Acetate | 16 | $852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $41 | $324,35476 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $18 | $56,57145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.
Other urology in Edina
- Steven BernsteinEdina$271K
- Joseph MahonEdina$86K
- Stephen OverholserEdina$20K
- Jason KemberlingEdina$19K
- Dean TortorelisEdina$19K
- Paul FaddenEdina$6K
- Jeffry TwidwellEdina$6K
- Rachel MannEdina$6K
- Chase SovellEdina$5K
- Matthew BraaschEdina$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.